New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:23 EDTSDT, GDOT, INSY, EXPE, DEPO, CPN, EZPW, BYIHigh option volume stocks
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 23, 2015
12:55 EDTINSYInsys Therapeutics plans to spend approximately $100M in 2016 on drug projects
Subscribe for More Information
12:54 EDTINSYInsys Therapeutics mentioned positively by Navellier
Subscribe for More Information
12:49 EDTINSYInsys Therapeutics says 'takes patient safety very seriously'
Subscribe for More Information
07:37 EDTDEPOHorizon Pharma reinstated with a Buy at Jefferies
Jefferies analyst David Steinberg reinstated Horizon Pharma (HZNP) with a Buy rating and reduced price target of $32. The company's standalone growth "appears healthy" and a near-term deal is likely following its failed attempt to acquire Depomed (DEPO), Steinberg tells investors in a research note.
November 20, 2015
09:10 EDTDEPOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Abercrombie & Fitch (ANF), up 16.3%... Foot Locker (FL), up 4.8%. ALSO HIGHER: Horizon Pharma (HZNP), up 1.6% after withdrawing offer to acquire Depomed (DEPO)... Nike (NKE), up 4.3% after announcing a $12B repurchase program, a two-for-one stock split, and that it will raise its dividend. DOWN AFTER EARNINGS: Nimble Storage (NMBL), down 45.3%... Mentor Graphics (MENT), down 28%. ALSO LOWER: Depomed, down 5.9% after Horizon Pharma withdrew its offer to acquire the company... Builders FirstSource (BLDR), down 3.7% after 7M share Spot Secondary priced at $13.25.
07:10 EDTEXPEExpedia outlook has improved, says Oppenheimer
Subscribe for More Information
05:17 EDTDEPODepomed comments on Horizon Pharma withdrawal of offer to acquire company
Subscribe for More Information
05:13 EDTDEPOHorizon Pharma withdraws offer to acquire Depomed
Horizon Pharma (HZNP) announced that at a hearing, Judge Peter Kirwan of the Superior Court of California for the County of Santa Clara granted Depomed's (DEPO) motion for preliminary injunctive relief against Horizon Pharma's alleged use of information that Depomed claimed was confidential. In his ruling, Judge Kirwan did not grant the injunctive relief Horizon Pharma had sought regarding the legality of Depomed's poison pill and certain of the bylaw amendments announced by Depomed's board of directors on July 13. While we strongly disagree with the court's ruling, we are withdrawing our offer to acquire Depomed," said Timothy P. Walbert, chairman, president and CEO, Horizon Pharma. "Today's ruling by the court does not affect our 2016 guidance or long-range plan or expectations. We have built a strong and diversified portfolio of medicines that we expect will exceed $750Mn in net sales in 2015 and we expect will drive nearly $1B in net sales in 2016. As we look to the future, we are committed to our strategy of complementing our strong organic growth, which has the potential to double our net sales to approximately $2B by 2020, with value enhancing acquisitions. While we are disappointed by the court's ruling, Depomed was only one of many attractive acquisition opportunities we have been actively pursuing."
November 19, 2015
15:02 EDTINSYInsys Therapeutics pulls out of presentation at Opco conference, SIRF says
Subscribe for More Information
13:24 EDTEXPEExpedia CEO says shut out of TripAdvisor Instant Booking for now, Skift says
Subscribe for More Information
November 18, 2015
10:10 EDTINSYOptions with decreasing implied volatility
Options with decreasing implied volatility: INSY PRGO SYF KSS LOCO ATML JWN JD MEG MWE
07:43 EDTINSYJefferies to hold a conference
Subscribe for More Information
November 17, 2015
16:59 EDTDEPODepomed acquires U.S. rights to pain product from Grunenthal
Subscribe for More Information
12:11 EDTEXPEExpedia management to meet with Guggenheim
Meeting to be held in FT. Lauderdale on November 18 hosted by Guggenheim.
10:11 EDTINSYOptions with decreasing implied volatility
Subscribe for More Information
06:57 EDTEXPEExpedia enters strategic technology partnership with SilverRail Technologies
SilverRail Technologies and Expedia announced a strategic technology partnership to power Expedia's global expansion in the rail business. SilverRail's global rail ticketing platform simplifies the process of accessing multiple rail companies through a standard interface. This will enable Expedia to deliver a simple, consistent search and booking experience to which their customers have become accustomed. Development has already begun, with platform launch expected in 2016.
November 16, 2015
10:25 EDTINSYOptions with decreasing implied volatility
Subscribe for More Information
10:07 EDTEXPEExpedia shares defended at Cowen
Subscribe for More Information
09:37 EDTEXPEActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
09:06 EDTINSYDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use